Circulating 25-hydroxyvitamin D (25-OHD) levels and prognosis among cancer patients: a systematic review
Menée à partir d'une revue systématique de la littérature publiée jusqu'en septembre 2013 (26 études), cette étude évalue l'association entre le niveau sérique de la 25-hydroxy-vitamine D, un métabolite de la vitamine D, et la survie chez les patients atteints d'un cancer
Circulating 25-hydroxyvitamin D (25-OHD) is associated with a reduction in risk of some cancers but its association with prognosis among cancer patients is poorly understood. In view of the increasing number of cancer survivors in the United States and the high prevalence of vitamin D deficiency among cancer patients, an evaluation of the role circulating 25-OHD in prognosis among cancer patients is essential. We conducted a systematic review of studies published in following databases: PubMed, OvidSP, BioMed Central, EMBASE, and Scopus till September 2013 using the following search terms: "vitamin D", "25-hydroxyvitamin D", "calcidiol", "cancer", "survival", "mortality", "prognosis". Our search yielded 1,397 articles. From the 1,397 articles, we identified 26 studies that evaluated the associations of circulating 25-OHD with prognosis among cancer patients. Evidence suggests that circulating 25-OHD levels may be associated with better prognosis in breast and colorectal cancer patients but there is paucity of information on its association with prognosis in other cancers. This review highlights the need for further studies evaluating the role of vitamin D in prognosis among cancer patients.
Cancer Epidemiology Biomarkers & Prevention , résumé, 2014